Investment
Features
FeesSafety
Academy
More
Pluang+

Compare State Street SPDR Bloomberg 1-3 Month T-Bill ETF (BIL) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance

State Street SPDR Bloomberg 1-3 Month T-Bill ETFTrade
Ginkgo Bioworks Holdings IncTrade

Price performance (Past 24H)

Key statistics

State Street SPDR Bloomberg 1-3 Month T-Bill ETF vs Ginkgo Bioworks Holdings Inc — how do they compare? State Street SPDR Bloomberg 1-3 Month T-Bill ETF trades at $91.5, while Ginkgo Bioworks Holdings Inc trades at $7.56 (market cap $515.15M). The key difference: State Street SPDR Bloomberg 1-3 Month T-Bill ETF is trading nearer its 52-week high, Ginkgo Bioworks Holdings Inc nearer its low. Which is the better fit depends on your goals.

BILDNA
Sector
Fixed IncomeHealth
52-Week High
$91.77$16.14
52-Week Low
$91.27$5.48
Market Cap
$515.15M
Enterprise Value
$617.10M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

State Street SPDR Bloomberg 1-3 Month T-Bill ETF

BIL trades at $91.48 with minimal daily movement (+0.03%), showing stability amid market volatility. The ETF maintains consistent dividend distributions of $0.27 per share quarterly, with recent institutional buying activity indicating professional confidence. Technical indicators show bearish momentum with moving averages signaling caution, though oscillators suggest potential stabilization near current levels.

As a short-term Treasury ETF, BIL offers capital preservation and steady income through Treasury bill exposure. Key risks include interest rate sensitivity and inflation pressures affecting Treasury yields. The fund's defensive positioning appeals to risk-averse investors seeking liquidity and minimal credit risk in uncertain markets.

Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks (DNA) trades at $7.97, down 6.24% today, reflecting ongoing operational challenges. The company reported Q2 2026 revenue of $20 million, a 48% year-over-year decline, as it shifts focus to autonomous lab systems. Despite beating EPS expectations in two of the last three quarters, net losses remain substantial with a -219.6% margin. Technical indicators show bearish momentum with support at $7 and resistance at $9.

DNA faces significant headwinds with declining revenue and persistent losses, though analyst sentiment is mixed with 45% buy ratings. The pivot to new business lines creates uncertainty, while cash burn and competitive pressures present substantial risks. Upside depends on successful execution of the strategic shift and path to profitability.

Returns comparison

Trailing returns across standard periods

About State Street SPDR Bloomberg 1-3 Month T-Bill ETF

BIL tracks the performance of short-term U.S. Treasury bills with maturities between 1 and 3 months. It is designed for investors seeking a highly liquid, low-risk vehicle for cash management and capital preservation.

Read more on BIL

About Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.

Read more on DNA